ASPARLAS (calaspargase pegol)

OFFICE ADMINISTRATION-IV 

Indications for Prior Authorization:

  • Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adults aged 1 month to 21 years

Patients must meet the following criteria for the indication(s) above:

  • 1 month to 21 years of age, AND
  • Diagnosis of acute lymphoblastic leukemia confirmed by an oncologist or hematologist

Contraindications:

  • History of serious hypersensitivity reactions to pegylated L-asparaginase
  • History of serious thrombosis during L-asparaginase therapy
  • History of serious pancreatitis related to previous L-asparaginase treatment
  • History of serious hemorrhagic events during previous L-asparaginase treatment
  • Severe hepatic impairment

Precautions:

  • Use in specific populations:
    • Breast-feeding considerations: not recommended by the manufacturer during therapy and for 3 months after the last Asparlas dose

Dosing:

  • 2500 units/m2 (as part of a combination chemotherapy regimen)
  • Not administered more frequently than every 21 days

Approval:

  • 1 year

 

Last review date: February 18, 2020

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone